Loading
Loading
Research Overview
Next-generation amylin analogue with enhanced AMY1-3 receptor affinity and pegylated pharmacokinetics enabling once-weekly dosing; activates brainstem and hypothalamic amylin receptors to produce appetite suppression and satiety complementary to GLP-1R agonism.
Overview
Petrelintide is a synthetic amylin analogue engineered for once-weekly subcutaneous administration, achieving this dosing frequency through structural modifications that enhance amylin receptor binding affinity and incorporate pharmacokinetic improvements (including pegylation) to extend half-life to approximately 8 days.
The amylin pathway provides appetite suppression and satiety signalling through brainstem and hypothalamic amylin receptors (AMY1-3) — a mechanism complementary to GLP-1 receptor agonism. Research has shown that combining GLP-1 and amylin pathway activation produces additive weight reduction beyond either alone, which has driven development of amylin analogues intended for combination with GLP-1 agonists.
Phase 2 data for petrelintide has demonstrated dose-dependent weight reduction with a generally milder gastrointestinal side effect profile than GLP-1 monotherapy, potentially enabling higher combined doses when used alongside semaglutide. The CagriSema (cagrilintide + semaglutide) combination programme has informed petrelintide's development direction.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, petrelintide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Next-generation amylin analogue with enhanced AMY1-3 receptor affinity and pegylated pharmacokinetics enabling once-weekly dosing; activates brainstem and hypothalamic amylin receptors to produce appetite suppression and satiety complementary to GLP-1R agonism.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.